REVUFORJ Gets FDA Patent Timer: Generic Delays on Deck
Published Date: 2/26/2026
Notice
Summary
The FDA has set the official review period for the drug REVUFORJ, which helps the company extend its patent and protect their invention longer. This affects the drug maker and anyone tracking patent timelines, with deadlines to challenge or comment by April 27 and August 25, 2026. It’s a key step in making sure the patent extension process is fair and on schedule, potentially impacting when generic versions can enter the market.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
FDA Sets REVUFORJ Review Length
The FDA determined REVUFORJ had a regulatory review period of 1,969 days total: 1,674 days in the testing phase and 295 days in the approval phase. Those totals are based on an investigational exemption effective June 28, 2019, an NDA submission on January 26, 2024, and approval on November 15, 2024.
Applicant Requests 525-Day Patent Extension
The patent applicant (Vitae Pharmaceuticals, LLC) has applied to the USPTO seeking 525 days of patent term extension for U.S. Patent No. 10,683,302 covering REVUFORJ. FDA's determination of the regulatory review period establishes the maximum potential length of any extension the USPTO may consider.
Determination May Affect Generic Entry Timing
FDA’s determination establishes the maximum potential patent extension period that the USPTO may use when calculating any patent term restoration, and the USPTO will apply statutory limitations in its final calculation. That process can affect when generic versions of REVUFORJ are legally able to enter the market.
Deadlines to Challenge or Petition
Anyone who believes the published dates are incorrect may ask for a redetermination by April 27, 2026, and any interested person may petition FDA about the applicant's diligence during the regulatory review period by August 25, 2026. Petitions must meet the requirements in 21 CFR 60.30 and be timely and properly filed.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
Previous / Next Documents
Previous: 2026-03843 — Agency Information Collection Activities: Proposed Request
The Social Security Administration wants your thoughts on some forms they use to pick people who manage benefits for others. They’re updating these forms and asking for feedback by April 27, 2026, to make sure the process is clear and easy. This affects individuals and organizations applying to be payees, with no new costs but a chance to reduce paperwork hassle.
Next: 2026-03848 — Determination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
The FDA has set the official review period for ORLYNVAH, a human drug, which helps decide how long its patent can be extended. This affects the drug’s maker by potentially giving them more time to protect their invention and earn money. If anyone thinks the dates are wrong or wants to challenge the company’s effort during review, they have until April 27 or August 25, 2026, to speak up.